News

The study was designed to allow US based investigators and the FDA to evaluate Rigerimod (Lupuzor) as a treatment for lupus before commencing a Phase III clinical trial.

Ablynx is developing a nanobody-based portfolio of therapeutics in a number of therapeutic areas, including inflammation, thrombosis, oncology and Alzheimer’s disease. Ablynx has over 25 programmes in its

Biaxin is in a group of drugs called macrolide antibiotics. It fights bacteria in the body. Biaxin is used to treat many different types of bacterial infections affecting

Kendle claimed that the new SEZ operations center integrates all the clinical support services which focus on delivery of clinical data management, medical writing, pharmacovigilance/safety, biostatistics/programming and other

Aphios said that the invention entails methods of purifying protein-containing polymeric microspheres/nanospheres from unused polymer and an apparatus therefore. Aphios claimed that the uniformity and integrity as well

Cognis is a supplier of solutions and products based on renewable raw materials for the health and nutrition market as well as the cosmetics, detergents and cleaners industries.

Valeant Pharma said that, since last year, it has experienced a shortage of Oxsoralen products due to an unanticipated change in the supplier of the product’s active ingredient.

Dr Amphlett and Dr Lutz have played central roles in establishing ImmunoGen’s product development capabilities. These functions complement the company’s research capabilities in ImmunoGen’s advancement of its own

Dapagliflozin, an investigational compound, is a potential sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers Squibb Company and AstraZeneca. The study also